MBI assessed as supplementary screening tool for women with dense breasts.
Molecular breast imaging (MBI) is effective as a supplementary screening tool to mammography for women with dense breasts, according to a study published in the American Journal of Roentgenology.
Researchers from Ohio, California, and New Hampshire performed a retrospective study to assess the utility of MBI as a supplementary screening tool for 1,696 women with dense breast tissue. They sought to determine cancer detection rates, recall rates, biopsy rates, and positive predictive values (PPVs).
The results showed that 13 mammographically occult malignancies were detected among the study group. Eleven were invasive, one was node positive, and one had unknown node positivity. Other findings showed:
• Lesion size ranged from 0.6 to 2.4 cm, mean 1.1 cm[[{"type":"media","view_mode":"media_crop","fid":"50915","attributes":{"alt":"©RSNA 2015.","class":"media-image media-image-right","id":"media_crop_9213433233653","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"6242","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 151px; width: 170px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©RSNA 2015.","typeof":"foaf:Image"}}]]
• Incremental cancer detection rate was 7.7%
• Recall rate was 8.4%
• Biopsy rate was 3.7%
• PPV for recall (PPV 1) was 9.1%
• PPV for biopsy (PPV 3) was 19.4%
While MBI does expose women to a higher radiation dose than does standard mammography, the effective dose from the MBI exam was 2.3 mSv, compared with a typical mammography dose of 0.56 mSv. “When incorporated into a community-based clinical practice environment, molecular breast imaging yielded a high incremental cancer detection rate of 7.7 percent at an acceptable radiation dose,” the researchers concluded.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.